# Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

> **NCT01828086** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 95 (actual)

## Conditions studied

- Chronic Plaque-type Psoriasis

## Interventions

- **BIOLOGICAL:** CJM112
- **BIOLOGICAL:** Secukinumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01828086
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2020-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01828086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01828086, "Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01828086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*